Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

184 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cardiovascular outcomes with sodium-glucose cotransporter-2 inhibitors vs other glucose-lowering drugs in 13 countries across three continents: analysis of CVD-REAL data.
Khunti K, Kosiborod M, Kim DJ, Kohsaka S, Lam CSP, Goh SY, Chiang CE, Shaw JE, Cavender MA, Tangri N, Franch-Nadal J, Holl RW, Jørgensen ME, Norhammar A, Eriksson JG, Zaccardi F, Karasik A, Magliano DJ, Thuresson M, Chen H, Wittbrodt E, Bodegård J, Surmont F, Fenici P; CVD-REAL Investigators and Study Group. Khunti K, et al. Cardiovasc Diabetol. 2021 Jul 31;20(1):159. doi: 10.1186/s12933-021-01345-z. Cardiovasc Diabetol. 2021. PMID: 34332558 Free PMC article.
Diabetic retinopathy is associated with the presence and burden of subclinical carotid atherosclerosis in type 1 diabetes.
Carbonell M, Castelblanco E, Valldeperas X, Betriu À, Traveset A, Granado-Casas M, Hernández M, Vázquez F, Martín M, Rubinat E, Lecube A, Franch-Nadal J, Fernández E, Puig-Domingo M, Avogaro A, Alonso N, Mauricio D. Carbonell M, et al. Cardiovasc Diabetol. 2018 May 4;17(1):66. doi: 10.1186/s12933-018-0706-z. Cardiovasc Diabetol. 2018. PMID: 29728117 Free PMC article.
Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors: an analysis from the CVD-REAL 2 multinational cohort study.
Kohsaka S, Lam CSP, Kim DJ, Cavender MA, Norhammar A, Jørgensen ME, Birkeland KI, Holl RW, Franch-Nadal J, Tangri N, Shaw JE, Ilomäki J, Karasik A, Goh SY, Chiang CE, Thuresson M, Chen H, Wittbrodt E, Bodegård J, Surmont F, Fenici P, Kosiborod M; CVD-REAL 2 Investigators and Study Group. Kohsaka S, et al. Lancet Diabetes Endocrinol. 2020 Jul;8(7):606-615. doi: 10.1016/S2213-8587(20)30130-3. Lancet Diabetes Endocrinol. 2020. PMID: 32559476
Analysis of the effectiveness of second oral glucose-lowering therapy in routine clinical practice from the mediterranean area: A retrospective cohort study.
Vlacho B, Mundet-Tudurí X, Mata-Cases M, Vallès-Callol JA, Real J, Farré M, Cos FX, Khunti K, Mauricio D, Franch-Nadal J. Vlacho B, et al. Diabetes Res Clin Pract. 2021 Jan;171:108616. doi: 10.1016/j.diabres.2020.108616. Epub 2020 Dec 10. Diabetes Res Clin Pract. 2021. PMID: 33310172 Free article.
Analysis of the Adherence and Safety of Second Oral Glucose-Lowering Therapy in Routine Practice From the Mediterranean Area: A Retrospective Cohort Study.
Vlacho B, Mata-Cases M, Mundet-Tudurí X, Vallès-Callol JA, Real J, Farre M, Cos X, Khunti K, Mauricio D, Franch-Nadal J. Vlacho B, et al. Front Endocrinol (Lausanne). 2021 Jul 14;12:708372. doi: 10.3389/fendo.2021.708372. eCollection 2021. Front Endocrinol (Lausanne). 2021. PMID: 34335477 Free PMC article.
All-cause and cardiorenal mortality in 6 million adults with and without type 2 diabetes: A comparative, trend analysis in Canada, Spain, and the UK.
Ling S, Zaccardi F, Vlacho B, Li P, Real Gatius J, Mata-Cases M, Franch-Nadal J, Kosiborod MN, Gillies C, Fenici P, Mauricio D, Shah BR, Khunti K. Ling S, et al. Diabetes Obes Metab. 2023 Jan;25(1):132-143. doi: 10.1111/dom.14856. Epub 2022 Sep 26. Diabetes Obes Metab. 2023. PMID: 36056765 Free PMC article.
184 results